FibroBiologics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
FBLG Nasdaq 2836 fibrobiologics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for FibroBiologics, Inc.

FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity - Sep 29th, 2026 6:30 am
Nova Minerals and FibroBiologics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV - Sep 25th, 2026 7:00 am
FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer - Sep 17th, 2026 6:30 am
Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications - Sep 8th, 2026 7:00 am
FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing - Sep 3rd, 2026 6:30 am
FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media - Sep 1st, 2026 6:30 am
FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial - Aug 27th, 2026 6:30 am
FibroBiologics advances diabetic ulcer trial with new drug shipment to Australia - Aug 27th, 2026 2:25 am
FibroBiologics Regains Compliance with Nasdaq Trading Rules - Aug 26th, 2026 6:30 am
FibroBiologics Appoints Leigh Steinberg to Board of Directors - Aug 24th, 2026 6:30 am
FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease - Aug 20th, 2026 6:30 am
FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints - Aug 18th, 2026 6:30 am
FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets - Aug 11th, 2026 6:30 am
FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage - Aug 5th, 2026 6:30 am
FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate - Jul 31st, 2026 3:34 pm
FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors - Jul 9th, 2026 6:30 am
FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial - Jul 7th, 2026 6:30 am
FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - Jun 30th, 2026 6:30 am
FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules - Jun 29th, 2026 2:01 pm
FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules - Jun 26th, 2026 6:30 am